Comparison of long-term pharmacodynamic actions of the synthetic small molecule HSP90 inhibitor AT13387 in multiple xenograft models

被引：2
|
作者：
Lyons, John
Curry, Jayne
Smyth, Tomoko
Harada, Isobel
Fazal, Lynsey
Reule, Matthias
Graham, Brent
Thompson, Neil
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-A217
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A217
引用
收藏
页数：3
相关论文
共 25 条
  • [1] Significance of long term pharmacodynamic actions of the HSP90 inhibitor AT13387
    Curry, Jayne
    Fazal, Lynsey
    Graham, Brent
    Harada, Isobel
    Lyons, John
    Reule, Matthias
    Smyth, Tomoko
    Thompson, Neil
    [J]. CANCER RESEARCH, 2009, 69
  • [2] Fragment-based drug discovery of the synthetic small molecule HSP90 inhibitor AT13387
    Murray, Christopher W.
    Carr, Maria G.
    Chessari, Gianni
    Congreve, Miles
    Coyle, Joseph E.
    Day, Philip J.
    Fazal, Lynsey
    Frederickson, Martyn
    Graham, Brent
    Lewis, Jonathan
    McMenamin, Rachel
    O'Brien, Alistair
    Patel, Sahil
    Williams, Glyn
    Woodhead, Andrew J.
    Woolford, Alison J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] Activity of the HSP90 Inhibitor, AT13387, in ALK-driven Tumor Models
    Wallis, N.
    Smyth, T.
    Munck, J.
    Rodriguez-Lopez, A.
    Lock, V.
    McMenamin, R.
    Thompson, N.
    Lyons, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 90 - 90
  • [4] Inhibition of Tumour Growth in a Pancreatic Cancer Xenograft Model by AT13387, an HSP90 Inhibitor
    Shaw, E.
    Thomas, A.
    Ghaneh, P.
    Greenhalf, W.
    Davies, M.
    Costello, E.
    Gibbs, F.
    Lyons, J.
    Neoptolemos, J. P.
    Sibson, D. R.
    [J]. PANCREAS, 2011, 40 (08) : 1353 - 1353
  • [5] The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
    Rodriguez-Lopez, Ana
    Smyth, Tomoko
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Lock, Victoria
    Taverna, Pietro
    Corringham, Robert
    Wallis, Nicola
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [6] The HSP90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
    Smyth, Tomoko
    Lewis, Jon
    Hearn, Keisha
    Thompson, Neil
    Lyons, John
    Wallis, Nicola G.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [7] AT13387, an HSP90 inhibitor, is effective in both vemurafenib-sensitive and -resistant melanoma models
    Rodriguez-Lopez, Ana M.
    Smyth, Tomoko
    Curry, Jayne
    Graham, Brent
    McMenamin, Rachel
    Lyons, John
    Thompson, Neil
    Wallis, Nicola
    [J]. CANCER RESEARCH, 2012, 72
  • [8] The HSP90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model
    Courtin, Aurelie
    Smyth, Tomoko
    Hearn, Keisha
    Lyons, John
    Thompson, Neil
    Wallis, Nicola G.
    [J]. CANCER RESEARCH, 2015, 75
  • [9] The HSP90 Inhibitor, AT13387, Is Effective In Mutant EGFR And ALK-positive NSCLC Models.
    Wallis, N. G.
    Smyth, T.
    Rodriguez-Lopez, A.
    McMenamin, R.
    Lock, V.
    Curry, J.
    Graham, B.
    Lyons, J.
    Thompson, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S254 - S254
  • [10] The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
    Smyth, Tomoko
    Van Looy, Thomas
    Curry, Jayne E.
    Rodriguez-Lopez, Ana M.
    Wozniak, Agnieszka
    Zhu, Meijun
    Donsky, Rachel
    Morgan, Jennifer G.
    Mayeda, Mark
    Fletcher, Jonathan A.
    Schoffski, Patrick
    Lyons, John
    Thompson, Neil T.
    Wallis, Nicola G.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (08) : 1799 - 1808
123